Human LILRB1 / CD85j / ILT2 Protein, His Tag (MALS verified)

Customer Reviews
Cat. No. / Size
Price
Qty
CDJ-H52H4-100ug
$360.00
CDJ-H52H4-1mg (500ug X 2)
$2380.00
ETA of in-stock products:2 business days

Product Details

  • Synonyms

    CD85J, LILRB1, CD85, ILT2, LIR1, MIR7

  • Source

    Human LILRB1, His Tag (CDJ-H52H4) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - His 458 (Accession # D9IDM8-1).

    Predicted N-terminus: Gly 24

    Request for sequence
  • Molecular Characterization

    LILRB1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 49.1 kDa. The protein migrates as 64-68 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    LILRB1 SDS-PAGE

    Human LILRB1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    LILRB1 SEC-MALS

    The purity of Human LILRB1, His Tag (Cat. No. CDJ-H52H4) is more than 95% and the molecular weight of this protein is around 52-71 kDa verified by SEC-MALS.

    Report
  • Bioactivity-SPR

     LILRB1 SPR

    Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Complex Protein (Cat. No. HLM-H82E4) captured on Biotin CAP-Series S Sensor Chip can bind Human LILRB1, His Tag (Cat. No. CDJ-H52H4) with an affinity constant of 10.8 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

Recent Advances

 
Drug Development Progress
  • English Name:

    Leukocyte immunoglobulin-like receptor B1

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    7 Details

  • Highest Development Stage:

    Phase 2 Clinical

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland